Nav: Home

Safety of bioabsorbable polymer against durable polymer DES in high-risk PCI patients

May 14, 2020

WASHINGTON - A novel study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) presented a safety advantage without compromising efficacy compared to durable polymer (DP) formulations. Subgroup findings from the TWILIGHT trial were presented today during the SCAI 2020 Scientific Sessions Virtual Conference.

The study examined the SYNERGY platform in a higher risk patient population than previously studied. In addition, the investigators evaluated the effect ticagrelor monotherapy in such patients, which has not been done in previous studies. Ticagrelor is a blood thinner that has been found to prevent stroke, heart attack, and other heart problems.

Investigators conducted a pre-specified analysis among patients enrolled in the TWILIGHT trial treated with the BP everolimus-eluting stent (BP-EES) or a DP-DES. Following successful percutaneous coronary intervention (PCI) and 3 months of ticagrelor plus aspirin, patients were randomized to aspirin or placebo for 1 year; DES choice was at physician discretion. The primary endpoint was target lesion failure (TLF) [composite of cardiac death, target vessel myocardial infarction (MI), clinically driven target lesion revascularization (TLR) or definite/probable stent thrombosis (ST)].

Patients receiving BP-EES (n = 653; 9.2%) were more frequently randomized in North America and had a lower frequency of prior MI compared to those receiving DP-DES (n = 6404; 90.8%); total stent length was approximately 39 mm in both groups. One-year rates of TLF were 6.4% and 6.1% in the BP-EES and DP-DES groups, respectively (p = 0.72). Analogous rates of def/prob ST and TLR were 0.8% vs 0.9% (p = 0.49) and 5.3% vs 4.4% (p = 0.96). The effect of ticagrelor monotherapy on ischemic and bleeding events was uniform across DES groups (all pint >0.10).

"Our work shows that the SYNERGY stent performs similarly to other durable polymer DES in relatively high-risk patients enrolled in the TWILIGHT trial," said Usman Baber, MD, lead author of the study. "This is a clinically relevant finding as it provides randomized evidence supporting the use of this platform in such patients. In addition, the effect of ticagrelor monotherapy on ischemic and bleeding events observed in the overall trial was preserved among patients receiving a SYNERGY DES, suggesting this strategy may be a safe alternative in high bleeding risk patients treated with the SYNERGY stent."

"These findings broaden the generalizability of adopting a strategy of P2Y12 inhibitor monotherapy to patients treated with different DES platforms," continued Baber. "In addition, our results provide reassurance that the SYNERGY platform performs similarly to other newer-generation DES in high-risk patients."

Abstract #11754 "Safety and efficacy of the biodegradable-polymer everolimus-eluting stent versus durable-polymer drug-eluting stents in high-risk patients undergoing PCI: Insights from the TWILIGHT trial." SCAI 2020 Scientific Sessions Virtual Conference, May 14-16, 2020.
-end-
About the Society for Cardiovascular Angiography and Interventions

The Society for Cardiovascular Angiography and Interventions (SCAI) is a professional member organization representing 5,000 invasive and interventional cardiologists in approximately 75 nations. SCAI's mission is to promote excellence invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. For more information about SCAI, visit http://www.scai.org and http://www.secondscount.org. Follow @SCAI on Twitter for the latest heart health news.

Society for Cardiovascular Angiography and Interventions

Related Ticagrelor Articles:

Safety of bioabsorbable polymer against durable polymer DES in high-risk PCI patients
A novel study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) presented a safety advantage without compromising efficacy compared to durable polymer (DP) formulations.
Precision medicine guides choice of better drug therapy in severe heart disease
Is personalized medicine cost-effective? Researchers have answered that question for one medical treatment, genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI.
Benefit seen for ticagrelor alone, without aspirin, in patients with ACS
The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Ticagrelor alone, without aspirin, shows benefit in patients with diabetes
Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.
Dropping aspirin for ticagrelor alone better in complex heart disease
The research, a subanalysis of the TWILIGHT trial, was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Genetic testing for antiplatelet therapy post-PCI misses cut in cardiovascular events
An international clinical trial that used genetic testing to guide which antiplatelet medication was given to patients following percutaneous coronary intervention (PCI) did not meet its stated goal for cutting in half the incidence of serious adverse cardiovascular events, such as heart attack and stroke, in the year following the procedure, according to study results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Additional heart artery stenting reduces risk of future heart attacks
Research has shown that patients who have had emergency heart attack treatment with heart artery stenting -- and have significant narrowings in their other untreated arteries -- can benefit from additional stenting to help prevent future heart attacks.
The Lancet journals: Papers at ESC Congress 2019
The following papers will be presented at the ESC Congress 2019, organised by the European Society of Cardiology in Paris and published simultaneously in either The Lancet or The Lancet Global Health journals.
For patients with diabetes, ticagrelor reduced heart attacks, strokes
In late-breaking clinical trial results presented in a Hot Line Session today at the European Society of Cardiology Congress 2019, investigators from Brigham and Women's Hospital and Greater Paris University Hospitals -- AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS).
New computer-based predictive tool more accurately forecasts outcomes for respiratory patients
Are electronic health records and computer calculations a better, more accurate way to predict clinical outcomes for patients with chronic obstructive pulmonary disease?
More Ticagrelor News and Ticagrelor Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

Uncounted
First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at Radiolab.org/donate.